JCV index and L-selectin for natalizumab-associated PML risk stratification

      Background: Long-term treatment with and the presence of anti-JCV antibodies in serum are associated with the risk to develop-induced PML. Recent data suggest that the level of anti-JCV antibodies in serum (JCV antibody index > 0.9) and/or the lack of L-selectin (CD62L) on cryopreserved CD4+ T cells (%CD62L + cells of CD4+ T cells < 21.6) could be biomarkers for higher PML risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect